Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD

Frontiers in Endocrinology

Volumn 6, Issue , 2015, Pages

  Inagaki, Takeshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

chronic inflammation; epigenetic regulation; ER stress; FGF21; NAFLD; NASH

Indexed keywords

EID: 85006185441     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00147     Document Type: Review

References (75)

1. Ornitz DM Itoh N. Fibroblast growth factors. Genome Biol (2001) 2:REVIEWS3005.10.1186/gb-2001-2-3-reviews300511276432
2. Angelin B Larsson TE Rudling M. Circulating fibroblast growth factors as metabolic regulators – a critical appraisal. Cell Metab (2012) 16:693–705.10.1016/j.cmet.2012.11.00123217254
3. Fon Tacer K Bookout AL Ding X Kurosu H John GB Wang L et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 24:2050–64.10.1210/me.2010-014220667984
4. Goetz R Beenken A Ibrahimi OA Kalinina J Olsen SK Eliseenkova AV et al. Molecular insights into the Klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 27:3417–28.10.1128/MCB.02249-0617339340
5. Markan KR Naber MC Ameka MK Anderegg MD Mangelsdorf DJ Kliewer SA et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes (2014) 63:4057–63.10.2337/db14-059525008183
6. Inagaki T Dutchak P Zhao G Ding X Gautron L Parameswara V et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab (2007) 5:415–25.10.1016/j.cmet.2007.05.00317550777
7. Badman MK Pissios P Kennedy AR Koukos G Flier JS Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab (2007) 5:426–37.10.1016/j.cmet.2007.05.00217550778
8. Lundasen T Hunt MC Nilsson LM Sanyal S Angelin B Alexson SE et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun (2007) 360:437–40.10.1016/j.bbrc.2007.06.06817601491
9. Patel R Bookout AL Magomedova L Owen BM Consiglio GP Shimizu M et al. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol Endocrinol (2015) 29:213–23.10.1210/me.2014-125925495872
10. Schaap FG Kremer AE Lamers WH Jansen PL Gaemers IC. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie (2013) 95:692–9.10.1016/j.biochi.2012.10.01923123503
11. De Sousa-Coelho AL Marrero PF Haro D. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J (2012) 443:165–71.10.1042/BJ2011174822233381
12. Kim KH Jeong YT Oh H Kim SH Cho JM Kim YN et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med (2013) 19:83–92.10.1038/nm.301423202295
13. Kim KH Kim SH Min YK Yang HM Lee JB Lee MS. Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One (2013) 8:e63517.10.1371/journal.pone.006351723667629
14. Lee JH Giannikopoulos P Duncan SA Wang J Johansen CT Brown JD et al. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med (2011) 17:812–5.10.1038/nm.234721666694
15. Iizuka K Takeda J Horikawa Y. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett (2009) 583:2882–6.10.1016/j.febslet.2009.07.05319660458
16. Wang H Qiang L Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol (2008) 28:188–200.10.1128/MCB.00992-0717954559
17. Moyers JS Shiyanova TL Mehrbod F Dunbar JD Noblitt TW Otto KA et al. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol (2007) 210:1–6.10.1002/jcp.2084717063460
18. Cyphert HA Ge X Kohan AB Salati LM Zhang Y Hillgartner FB. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem (2012) 287:25123–38.10.1074/jbc.M112.37590722661717
19. Uebanso T Taketani Y Yamamoto H Amo K Tanaka S Arai H et al. Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet. J Nutr Biochem (2012) 23:785–90.10.1016/j.jnutbio.2011.03.02321889884
20. Archer A Venteclef N Mode A Pedrelli M Gabbi C Clement K et al. Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice. Mol Endocrinol (2012) 26:1980–90.10.1210/me.2012-115123073827
21. Owen BM Mangelsdorf DJ Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab (2015) 26:22–9.10.1016/j.tem.2014.10.00225476453
22. Izumiya Y Bina HA Ouchi N Akasaki Y Kharitonenkov A Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett (2008) 582:3805–10.10.1016/j.febslet.2008.10.02118948104
23. Hondares E Iglesias R Giralt A Gonzalez FJ Giralt M Mampel T et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 286:12983–90.10.1074/jbc.M110.21588921317437
24. Dutchak PA Katafuchi T Bookout AL Choi JH Yu RT Mangelsdorf DJ et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell (2012) 148:556–67.10.1016/j.cell.2011.11.06222304921
25. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr (2006) 26:1–22.10.1146/annurev.nutr.26.061505.111258
26. Sakakibara I Fujino T Ishii M Tanaka T Shimosawa T Miura S et al. Fasting-induced hypothermia and reduced energy production in mice lacking acetyl-CoA synthetase 2. Cell Metab (2009) 9:191–202.10.1016/j.cmet.2008.12.00819187775
27. Potthoff MJ Inagaki T Satapati S Ding X He T Goetz R et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A (2009) 106:10853–8.10.1073/pnas.090418710619541642
28. Kharitonenkov A Shiyanova TL Koester A Ford AM Micanovic R Galbreath EJ et al. FGF-21 as a novel metabolic regulator. J Clin Invest (2005) 115:1627–35.10.1172/JCI2360615902306
29. Wente W Efanov AM Brenner M Kharitonenkov A Koster A Sandusky GE et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes (2006) 55:2470–8.10.2337/db05-143516936195
30. Owen BM Ding X Morgan DA Coate KC Bookout AL Rahmouni K et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab (2014) 20:670–7.10.1016/j.cmet.2014.07.01225130400
31. Inagaki T Lin VY Goetz R Mohammadi M Mangelsdorf DJ Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab (2008) 8:77–83.10.1016/j.cmet.2008.05.00618585098
32. Owen BM Bookout AL Ding X Lin VY Atkin SD Gautron L et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med (2013) 19:1153–6.10.1038/nm.325023933983
33. Wei W Dutchak PA Wang X Ding X Wang X Bookout AL et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A (2012) 109:3143–8.10.1073/pnas.120079710922315431
34. Bornstein S Brown SA Le PT Wang X DeMambro V Horowitz MC et al. FGF-21 and skeletal remodeling during and after lactation in C57BL/6J mice. Endocrinology (2014) 155:3516–26.10.1210/en.2014-108324914939
35. Zhang J Kaasik K Blackburn MR Lee CC. Constant darkness is a circadian metabolic signal in mammals. Nature (2006) 439:340–3.10.1038/nature0436816421573
36. Zhang Y Xie Y Berglund ED Coate KC He TT Katafuchi T et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife (2012) 1:e00065.10.7554/eLife.0006523066506
37. Bookout AL de Groot MH Owen BM Lee S Gautron L Lawrence HL et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med (2013) 19:1147–52.10.1038/nm.324923933984
38. Nelson BT Ding X Boney-Montoya J Gerard RD Kliewer SA Andrews MT. Metabolic hormone FGF21 is induced in ground squirrels during hibernation but its overexpression is not sufficient to cause torpor. PLoS One (2013) 8:e53574.10.1371/journal.pone.005357423301087
39. Fisher FM Kleiner S Douris N Fox EC Mepani RJ Verdeguer F et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev (2012) 26:271–81.10.1101/gad.177857.11122302939
40. Sharp LZ Shinoda K Ohno H Scheel DW Tomoda E Ruiz L et al. Human BAT possesses molecular signatures that resemble beige/brite cells. PLoS One (2012) 7:e49452.10.1371/journal.pone.004945223166672
41. Lee P Linderman JD Smith S Brychta RJ Wang J Idelson C et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab (2014) 19:302–9.10.1016/j.cmet.2013.12.01724506871
42. Chartoumpekis DV Habeos IG Ziros PG Psyrogiannis AI Kyriazopoulou VE Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med (2011) 17:736–40.10.2119/molmed.2011.0007521373720
43. Adams AC Yang C Coskun T Cheng CC Gimeno RE Luo Y et al. The breadth of FGF21’s metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab (2012) 2:31–7.10.1016/j.molmet.2012.08.00724024127
44. Emanuelli B Vienberg SG Smyth G Cheng C Stanford KI Arumugam M et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest (2014) 124:515–27.10.1172/JCI6735324401271
45. Lee P Werner CD Kebebew E Celi FS. Functional thermogenic beige adipogenesis is inducible in human neck fat. Int J Obes (Lond) (2014) 38:170–6.10.1038/ijo.2013.8223736373
46. Veniant MM Sivits G Helmering J Komorowski R Lee J Fan W et al. Pharmacologic effects of FGF21 are independent of the “browning” of white adipose tissue. Cell Metab (2015) 21:731–8.10.1016/j.cmet.2015.04.01925955208
47. Samms RJ Smith DP Cheng CC Antonellis PP Perfield JW II Kharitonenkov A et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep (2015) 11:991–9.10.1016/j.celrep.2015.04.046
48. Liu J Xu Y Hu Y Wang G. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism (2015) 64:380–90.10.1016/j.metabol.2014.11.00925516477
49. Tanaka N Takahashi S Fang ZZ Matsubara T Krausz KW Qu A et al. Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta (2014) 1841:1596–607.10.1016/j.bbalip.2014.08.01525178843
50. Fisher FM Chui PC Nasser IA Popov Y Cunniff JC Lundasen T et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology (2014) 147:1073–83e6.10.1053/j.gastro.2014.07.04425083607
51. Jha P Knopf A Koefeler H Mueller M Lackner C Hoefler G et al. Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). Biochim Biophys Acta (2014) 1842:959–70.10.1016/j.bbadis.2014.02.01224594481
52. Li H Dong K Fang Q Hou X Zhou M Bao Y et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol (2013) 58:557–63.10.1016/j.jhep.2012.10.02923142063
53. Shen J Chan HL Wong GL Choi PC Chan AW Chan HY et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol (2012) 56:1363–70.10.1016/j.jhep.2011.12.02522314419
54. Dushay J Chui PC Gopalakrishnan GS Varela-Rey M Crawley M Fisher FM et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology (2010) 139:456–63.10.1053/j.gastro.2010.04.05420451522
55. Yilmaz Y Eren F Yonal O Kurt R Aktas B Celikel CA et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest (2010) 40:887–92.10.1111/j.1365-2362.2010.02338.x20624171
56. Li H Fang Q Gao F Fan J Zhou J Wang X et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol (2010) 53:934–40.10.1016/j.jhep.2010.05.01820675007
57. Hino S Nagaoka K Nakao M. Metabolism-epigenome crosstalk in physiology and diseases. J Hum Genet (2013) 58:410–5.10.1038/jhg.2013.5723719186
58. Lu C Thompson CB. Metabolic regulation of epigenetics. Cell Metab (2012) 16:9–17.10.1016/j.cmet.2012.06.001
59. Wan XS Lu XH Xiao YC Lin Y Zhu H Ding T et al. ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. Biomed Res Int (2014) 2014:807874.10.1155/2014/80787424900988
60. Kim SH Kim KH Kim HK Kim MJ Back SH Konishi M et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia (2015) 58:809–18.10.1007/s00125-014-3475-625537833
61. Jiang S Yan C Fang QC Shao ML Zhang YL Liu Y et al. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem (2014) 289:29751–65.10.1074/jbc.M114.56596025170079
62. Shimizu M Morimoto H Maruyama R Inoue J Sato R. Selective regulation of FGF19 and FGF21 expression by cellular and nutritional stress. J Nutr Sci Vitaminol (Tokyo) (2015) 61:154–60.10.3177/jnsv.61.15426052146
63. Dong K Li H Zhang M Jiang S Chen S Zhou J et al. Endoplasmic reticulum stress induces up-regulation of hepatic beta-Klotho expression through ATF4 signaling pathway. Biochem Biophys Res Commun (2015) 459:300–5.10.1016/j.bbrc.2015.02.10425727012
64. Kotulak T Drapalova J Kopecky P Lacinova Z Kramar P Riha H et al. Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiol Res (2011) 60:757–67.
65. Hulejova H Andres Cerezo L Kuklova M Pecha O Vondracek T Pavelka K et al. Novel adipokine fibroblast growth factor 21 is increased in rheumatoid arthritis. Physiol Res (2012) 61:489–94.22881230
66. Chi O Wei L Kun L Mingyan C Jianping L. The effect of fibroblast growth factor 21 on type 2 diabetic inflammation biomarkers. J Hunan Norm Univ (Med Sci) (2012) 2:004.
67. Diaz-Delfin J Hondares E Iglesias R Giralt M Caelles C Villarroya F. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology (2012) 153:4238–45.10.1210/en.2012-119322778214
68. Feingold KR Grunfeld C Heuer JG Gupta A Cramer M Zhang T et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology (2012) 153:2689–700.10.1210/en.2011-149622474187
69. Gaich G Chien JY Fu H Glass LC Deeg MA Holland WL et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab (2013) 18:333–40.10.1016/j.cmet.2013.08.00524011069
70. Galman C Lundasen T Kharitonenkov A Bina HA Eriksson M Hafstrom I et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab (2008) 8:169–74.10.1016/j.cmet.2008.06.01418680716
71. Chavez AO Molina-Carrion M Abdul-Ghani MA Folli F Defronzo RA Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care (2009) 32:1542–6.10.2337/dc09-068419487637
72. Yu H Xia F Lam KS Wang Y Bao Y Zhang J et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem (2011) 57:691–700.10.1373/clinchem.2010.15518421325103
73. Gimeno RE Moller DE. FGF21-based pharmacotherapy – potential utility for metabolic disorders. Trends Endocrinol Metab (2014) 25:303–11.10.1016/j.tem.2014.03.00124709036
74. Liu JJ Foo JP Liu S Lim SC. The role of fibroblast growth factor 21 in diabetes and its complications: a review from clinical perspective. Diabetes Res Clin Pract (2015) 108:382–9.10.1016/j.diabres.2015.02.03225796513
75. Wu S Levenson A Kharitonenkov A De Luca F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J Biol Chem (2012) 287:26060–7.10.1074/jbc.M112.34370722696219